drugset / Trial / NCT03560258
HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) Vaccine Study
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study evaluated the safety, immunogenicity, and preliminary assessment of efficacy of a novel vaccine encoding conserved elements (CE) of the HIV-1 Gag core protein, p24Gag, as a therapeutic vaccine in HIV-1 infected persons who were on antiretroviral therapy (ART). The study aimed to induce potent virus-specific cytotoxic T lymphocytes (CTL) responses.
Timeline
- Start
- 2019-03-26
- Primary completion
- 2021-02-10
- Completion
- 2021-02-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | full-length p55^gag pDNA vaccine | Vaccine | 2 mg | Other |
| Subject | full-length p55^gag pDNA vaccine | Vaccine | 4 mg | Other |
| Subject | p24CE1/2 pDNA vaccine | Vaccine | 2 mg | Other |